In an industry that has historically been siloed and secretive, the nonprofit collaboration known as TransCelerate BioPharma, Inc. (TransCelerate) is a clear indicator of change. It was formed in 2012 by a group of innovative thinkers and doers from a handful of leading life sciences organizations, with the mission to “collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines.”
One of TransCelerate’s areas of focus is improving the site investigator experience. To that end, the group has created something called the Shared Investigator Platform (SIP), designed to serve as a single, cloud-based, digital interface for all clinical investigators conducting research for any of the TransCelerate member companies. To date, those member companies include AbbVie, Allergan, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, EMD Serono Merck, GlaxoSmithKline, Johnson & Johnson, Lilly, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Shionogi, and UCB.
The concept of the SIP is quite noble and has the potential to vastly improve the experience of investigators and site personnel working on clinical trials. But it also has many inherent challenges that should be carefully considered.
Over the next few weeks, this series of blog posts will discuss the benefits and challenges associated with adopting the SIP, and offer SIP-related recommendations for companies that are considering joining TransCelerate, as well as those that are already members.
Stay tuned! In the meantime, check out this brief video that describes a project we completed for one of the TransCelerate member companies, and fill out the form below to download our related guide, Perspectives on the TransCelerate Shared Investigator Platform.
